Rehabilitation Therapy Utilization in Patients with Parkinson’s Disease in Korea

Table 1

Characteristics of patients with Parkinson’s disease in each 3-year study period.

Characteristics	2004–2006		2007–2009		2010–2012		2013–2015
	No.	%	No.	%	No.	%	No.	%
Total	384	100	855	100	1023	100	1221	100
Sex
Male	141	37.68	321	37.54	401	39.20	483	39.56
Female	243	62.32	534	62.46	622	60.80	738	60.44
Age (y)
0–59	64	16.67	97	11.35	105	10.26	121	9.91
60–69	159	41.40	232	27.13	249	24.34	276	22.60
70–79	129	33.59	385	45.03	480	46.92	545	44.64
80+	32	8.33	141	16.49	189	18.48	279	22.85
Income
N/A	0	0	95	11.11	77	7.53	74	6.06
Low	92	23.96	171	20.00	193	18.87	253	20.72
Middle	149	38.80	283	33.10	357	34.90	435	35.63
High	143	37.24	306	35.79	396	38.71	459	37.59
Region of residence
Seoul/Incheon	96	25.00	211	24.68	252	24.63	293	24.00
Gyeonggi/Gangwon	84	21.88	187	21.87	240	23.46	314	25.72
Busan/Daegu/Ulsan/Gyeongsang	91	23.70	215	25.15	262	25.61	328	26.86
Daejeon/Sejong/Chungcheong	45	11.72	96	11.23	116	11.34	105	8.60
Gwangju/Jeolla/Jeju	68	17.71	146	17.08	153	14.96	181	14.82
Comorbidities
No	314	81.77	694	81.17	857	83.77	1090	89.27
Yes	70	18.23	161	18.83	166	16.23	131	10.73
Disability grade
None	280	72.92	529	61.87	620	60.61	813	66.58
Mild to moderate (3–6)	59	15.36	189	22.11	249	24.34	323	26.45
Severe (1-2)	45	11.72	137	16.02	154	15.05	85	6.96
Types of antiparkinsonian medications
1-2	219	57.03	531	62.11	632	61.78	764	62.57
3-4	98	25.52	216	25.26	274	26.78	285	23.34
≥5	67	17.45	108	12.63	117	11.44	172	14.09
Levodopa-equivalent dose
<200	69	17.97	165	19.30	195	19.06	234	19.16
≥200, <400	126	32.81	345	40.35	389	38.03	467	38.25
≥400, <600	89	23.18	164	19.18	207	20.23	256	20.97
≥600, <800	46	11.98	70	8.19	105	10.26	118	9.66
≥800	54	14.06	111	12.98	127	12.41	146	11.96
Number of visits
Neurologists	6003	—	12546	—	16895	—	21652	—
Physiatrists	221	—	824	—	2013	—	3550	—